Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)
NCT ID: NCT00103922
Last Updated: 2016-10-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
600 participants
INTERVENTIONAL
2004-11-30
2007-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
cilomilast
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cilomilast
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Significant stomach or intestinal disease.
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Jasper, Alabama, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Tempe, Arizona, United States
GSK Investigational Site
Berkeley, California, United States
GSK Investigational Site
Carmichael, California, United States
GSK Investigational Site
Fullerton, California, United States
GSK Investigational Site
Long Beach, California, United States
GSK Investigational Site
Long Beach, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Murrieta, California, United States
GSK Investigational Site
Rancho Mirage, California, United States
GSK Investigational Site
Riverside, California, United States
GSK Investigational Site
Sacramento, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
San Jose, California, United States
GSK Investigational Site
Sepulveda, California, United States
GSK Investigational Site
Stockton, California, United States
GSK Investigational Site
Torrance, California, United States
GSK Investigational Site
Vista, California, United States
GSK Investigational Site
Walnut Creek, California, United States
GSK Investigational Site
Boulder, Colorado, United States
GSK Investigational Site
Colorado Springs, Colorado, United States
GSK Investigational Site
Denver, Colorado, United States
GSK Investigational Site
Englewood, Colorado, United States
GSK Investigational Site
Fort Collins, Colorado, United States
GSK Investigational Site
Wheat Ridge, Colorado, United States
GSK Investigational Site
Hartford, Connecticut, United States
GSK Investigational Site
Stamford, Connecticut, United States
GSK Investigational Site
Waterbury, Connecticut, United States
GSK Investigational Site
Aventura, Florida, United States
GSK Investigational Site
Brandon, Florida, United States
GSK Investigational Site
DeLand, Florida, United States
GSK Investigational Site
Fort Lauderdale, Florida, United States
GSK Investigational Site
Largo, Florida, United States
GSK Investigational Site
Longwood, Florida, United States
GSK Investigational Site
Melbourne, Florida, United States
GSK Investigational Site
Panama City, Florida, United States
GSK Investigational Site
Pensacola, Florida, United States
GSK Investigational Site
Tamarac, Florida, United States
GSK Investigational Site
Tampa, Florida, United States
GSK Investigational Site
West Palm Beach, Florida, United States
GSK Investigational Site
Atlanta, Georgia, United States
GSK Investigational Site
Decatur, Georgia, United States
GSK Investigational Site
Coeur d'Alene, Idaho, United States
GSK Investigational Site
Normal, Illinois, United States
GSK Investigational Site
Evansville, Indiana, United States
GSK Investigational Site
South Bend, Indiana, United States
GSK Investigational Site
Wichita, Kansas, United States
GSK Investigational Site
Madisonville, Kentucky, United States
GSK Investigational Site
Lafayette, Louisiana, United States
GSK Investigational Site
New Orleans, Louisiana, United States
GSK Investigational Site
Slidell, Louisiana, United States
GSK Investigational Site
Sunset, Louisiana, United States
GSK Investigational Site
Boston, Massachusetts, United States
GSK Investigational Site
Cadillac, Michigan, United States
GSK Investigational Site
Minneapolis, Minnesota, United States
GSK Investigational Site
Jefferson City, Missouri, United States
GSK Investigational Site
Saint Charles, Missouri, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
Billings, Montana, United States
GSK Investigational Site
Missoula, Montana, United States
GSK Investigational Site
Las Vegas, Nevada, United States
GSK Investigational Site
Cherry Hill, New Jersey, United States
GSK Investigational Site
Bronxville, New York, United States
GSK Investigational Site
Cortland, New York, United States
GSK Investigational Site
Larchmont, New York, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
Chapel Hill, North Carolina, United States
GSK Investigational Site
Charlotte, North Carolina, United States
GSK Investigational Site
Elizabeth City, North Carolina, United States
GSK Investigational Site
High Point, North Carolina, United States
GSK Investigational Site
Statesville, North Carolina, United States
GSK Investigational Site
Chardon, Ohio, United States
GSK Investigational Site
Columbus, Ohio, United States
GSK Investigational Site
Dayton, Ohio, United States
GSK Investigational Site
Sylvania, Ohio, United States
GSK Investigational Site
Lake Oswego, Oregon, United States
GSK Investigational Site
Medford, Oregon, United States
GSK Investigational Site
Portland, Oregon, United States
GSK Investigational Site
Allentown, Pennsylvania, United States
GSK Investigational Site
Downington, Pennsylvania, United States
GSK Investigational Site
Elverson, Pennsylvania, United States
GSK Investigational Site
Erie, Pennsylvania, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, United States
GSK Investigational Site
Swarthmore, Pennsylvania, United States
GSK Investigational Site
East Providence, Rhode Island, United States
GSK Investigational Site
Charleston, South Carolina, United States
GSK Investigational Site
Gaffney, South Carolina, United States
GSK Investigational Site
Greer, South Carolina, United States
GSK Investigational Site
Simpsonville, South Carolina, United States
GSK Investigational Site
Spartanburg, South Carolina, United States
GSK Investigational Site
Bristol, Tennessee, United States
GSK Investigational Site
Chattanooga, Tennessee, United States
GSK Investigational Site
Johnson City, Tennessee, United States
GSK Investigational Site
Knoxville, Tennessee, United States
GSK Investigational Site
Corsicana, Texas, United States
GSK Investigational Site
Dallas, Texas, United States
GSK Investigational Site
Fort Worth, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
San Antonio, Texas, United States
GSK Investigational Site
Salt Lake City, Utah, United States
GSK Investigational Site
Richmond, Virginia, United States
GSK Investigational Site
Richmond, Virginia, United States
GSK Investigational Site
Bellingham, Washington, United States
GSK Investigational Site
Spokane, Washington, United States
GSK Investigational Site
Spokane, Washington, United States
GSK Investigational Site
Tacoma, Washington, United States
GSK Investigational Site
Morgantown, West Virginia, United States
GSK Investigational Site
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Statistical Analysis Plan
View DocumentDocument Type: Study Protocol
View DocumentDocument Type: Clinical Study Report
View DocumentDocument Type: Informed Consent Form
View DocumentDocument Type: Individual Participant Data Set
View DocumentDocument Type: Dataset Specification
View DocumentRelated Links
Access external resources that provide additional context or updates about the study.
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIL103657
Identifier Type: -
Identifier Source: org_study_id